Last reviewed · How we verify
NCT06874608: JIA-ED
Evaluation of the Efficacy and Tolerability of an Exclusion Diet in Patients With Juvenile Idiopathic Arthritis
NA trial testing complete, polymeric formula, fiber, lactose and gluten free in Juvenile Idiopathic Arthritis (JIA) in 20 participants. Currently enrolling.
15 May 2025
Quick facts
| Lead sponsor | Meyer Children's Hospital IRCCS |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 20 |
| Start date | 12 December 2024 |
| Primary completion | 15 May 2025 |
| Estimated completion | 15 November 2025 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- complete, polymeric formula, fiber, lactose and gluten free
Conditions studied
- Juvenile Idiopathic Arthritis (JIA) — all drugs for Juvenile Idiopathic Arthritis (JIA) →
Sponsor
Meyer Children's Hospital IRCCS
Who can join
Adults 6 to 18, any sex, with Juvenile Idiopathic Arthritis (JIA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The JIA-ED study is a pilot project. Based on experience in another inflammatory disease, a 4-week period was extrapolated as sufficient to assess the effectiveness of the experimental intervention. This observation is supported by literature data showing that, halfway through phase I of the CDED (Crohn Diseasse Exclusion Diet), it is already possible to identify a subset of patients with Crohn's disease who are responsive to the dietary treatment and who also have a higher likelihood of achieving clinical remission by the end of the first phase of the diet itself.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Micronutrients in Autoimmune Diseases: Shining a Light on Vitamin D, Cobalamin, Folate, and Iron Metabolism
Triggianese P, Ramirez G, Cedola F, Nicola S, et al · · 2026
Verify or expand the search:
- PubMed search for NCT06874608
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Juvenile Idiopathic Arthritis (JIA)
Currently open trials in the same condition.
- NCT07087912 — Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases · Phase 4 · recruiting
- NCT07185750 — Investigation of Catastrophizing of Pain Reported by Parents in JIA Patients · recruiting
- NCT07234747 — Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis · NA · recruiting
- NCT06806774 — Reliability and Validity of the Glittre Activities of Daily Living Test in Children and Adolescents With Juvenile Idiopa · recruiting
- NCT06862843 — Study on Eating Habits and Association with "omic" Profiles in Families with a Subject Affected by a Chronic Immune-medi · recruiting
Other Meyer Children's Hospital IRCCS trials
Trials by the same sponsor.
- NCT07412782 — REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD) · NA · recruiting
- NCT07363304 — Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People Wi · recruiting
- NCT07412769 — ASMact: Study on Management of Bronchial Asthma · recruiting
- NCT07468461 — CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome · recruiting
- NCT07348263 — EFESO: Study on Juvenile Onset Eosinophilic Fasciitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06874608 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Meyer Children's Hospital IRCCS
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874608.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing